These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35011801)

  • 1. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients.
    Berar-Yanay N; Freiman S; Shapira M; Saffoury A; Elemy A; Hamze M; Elhaj M; Zaher M; Matanis L; Armaly ZA
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy.
    Glowinska I; Labij-Reduta B; Juzwiuk J; Lukaszewicz M; Pietruczuk A; Poplawska A; Daniluk-Jamro A; Kakareko K; Rydzewska-Rosolowska A; Naumnik B; Koc-Zorawska E; Zorawski M; Hryszko T
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis.
    Li T; Gandra S; Reske KA; Olsen MA; Bommarito S; Miller C; Hock KG; Ballman CA; Su C; Le Dang N; Kwon JH; Warren DK; Fraser VJ; Farnsworth CW;
    Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e48. PubMed ID: 36310813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
    Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
    CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave.
    Beilhack G; Monteforte R; Frommlet F; Reindl-Schwaighofer R; Strassl R; Vychytil A
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose.
    Angel-Korman A; Peres E; Bryk G; Lustig Y; Indenbaum V; Amit S; Rappoport V; Katzir Z; Yagil Y; Iaina NL; Leiba A; Brosh-Nissimov T
    Clin Kidney J; 2022 Feb; 15(2):226-234. PubMed ID: 35140934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients.
    Agur T; Ben-Dor N; Herman-Edelstein M; Steinmetz T; Lichtenberg S; Schneider S; Yahav D; Rozen-Zvi B; Zingerman B
    Front Med (Lausanne); 2022; 9():781888. PubMed ID: 35402451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose.
    Biedunkiewicz B; Tylicki L; Ślizień W; Lichodziejewska-Niemierko M; Dąbrowska M; Kubanek A; Rodak S; Polewska K; Tylicki P; Renke M; Dębska-Ślizień A
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
    Lacson E; Argyropoulos CP; Manley HJ; Aweh G; Chin AI; Salman LH; Hsu CM; Johnson DS; Weiner DE
    medRxiv; 2021 Apr; ():. PubMed ID: 33880482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.